Display options
Cite
Scalese MJ, Herring HR, Rathbun RC, et al. Propofol-associated QTc prolongation. Ther Adv Drug Saf. 2016;7(3):68-78doi: 10.1177/2042098616641354.
Scalese, M. J., Herring, H. R., Rathbun, R. C., Skrepnek, G. H., & Ripley, T. L. (2016). Propofol-associated QTc prolongation. Therapeutic advances in drug safety, 7(3), 68-78. https://doi.org/10.1177/2042098616641354
Scalese, Michael J, et al. "Propofol-associated QTc prolongation." Therapeutic advances in drug safety vol. 7,3 (2016): 68-78. doi: https://doi.org/10.1177/2042098616641354
Scalese MJ, Herring HR, Rathbun RC, Skrepnek GH, Ripley TL. Propofol-associated QTc prolongation. Ther Adv Drug Saf. 2016 Jun;7(3):68-78. doi: 10.1177/2042098616641354. Epub 2016 Apr 01. PMID: 27298717; PMCID: PMC4892405.
Copy Download .nbib Format: NLM
Share it on

Ther Adv Drug Saf. 2016 Jun;7(3):68-78. doi: 10.1177/2042098616641354. Epub 2016 Apr 01.

Propofol-associated QTc prolongation.

Therapeutic advances in drug safety

Michael J Scalese, Holly R Herring, R Chris Rathbun, Grant H Skrepnek, Toni L Ripley

Affiliations

  1. Auburn University Assistant Clinical Professor, Department of Pharmacy Practice Auburn University Harrison School of Pharmacy 650 Clinic Drive, Rm 2100 Mobile, AL 36688.
  2. Pharmacist, Department of Pharmacy, Integris Health Edmond, 4801 Integris Parkway, Edmond Oklahoma 73112.
  3. Professor and Chair, Department of Pharmacy: Clinical and Administrative Sciences, University of Oklahoma College of Pharmacy, 1110 N Stonewall Ave, Oklahoma City, OK 73117.
  4. Associate Professor, Department of Pharmacy: Clinical and Administrative Sciences, University of Oklahoma College of Pharmacy, 1110 N Stonewall Ave, Oklahoma City, OK 73117.

PMID: 27298717 PMCID: PMC4892405 DOI: 10.1177/2042098616641354

Abstract

OBJECTIVES: Propofol is a preferred agent for sedation in patients in the intensive care unit (ICU) due, in part, to its established safety profile. Despite this, recent case reports have suggested a potential for prolongation of the corrected QT interval (QTc) in ICU patients receiving propofol, though limited empirical work has been conducted to evaluate this association. As such, the purpose of this study was to assess the relationship between propofol infusion and QTc prolongation in a historical cohort of ICU patients.

METHODS: A single-center, historical, observational, pre-post cohort analysis of medical records from admitted patients ⩾18 years old with cardiovascular disease was conducted, involving cases who received propofol infusion for ⩾3 hours with sequential electrocardiogram monitoring from 2006 to 2012. A multivariable, generalized linear model regression was employed to assess the primary outcome of on-propofol QTc interval (QTc2), controlling for various demographic and clinical factors.

RESULTS: A total of 96 patients met inclusion criteria, averaging 56.1 ± 14.1 years of age and 86.1 ± 25.0 kg, with 37.5% being female. A mean prolongation in QTc interval of 30.4 ± 55.5 ms (p < 0.001) was observed during the propofol infusion, with 43.8% of cases exhibiting an on-infusion QTc2 of ⩾ 500 ms. Regression analyses suggested that prolongation in on-propofol QTc was independently associated with baseline QTc interval and amiodarone use, while weight as inversely associated with QTc2 (p < 0.05).

CONCLUSION: This historical cohort analysis of adult ICU patients receiving propofol suggests that on-infusion QTc prolongation was associated with increasing baseline QTc interval and with amiodarone use. Further research is needed to evaluate the clinical significance and cause-and-effect relationship between potential QTc changes and propofol use in the ICU.

Keywords: QTc prolongation; intensive care; propofol; safety

References

  1. Crit Care Med. 2012 Mar;40(3):823-8 - PubMed
  2. Crit Care Med. 2008 Aug;36(8):2281-7 - PubMed
  3. J Clin Monit Comput. 2013 Jun;27(3):243-8 - PubMed
  4. J Cardiovasc Risk. 2001 Aug;8(4):227-33 - PubMed
  5. Crit Care Med. 2013 Jan;41(1):263-306 - PubMed
  6. Anesthesiology. 2004 Feb;100(2):338-46 - PubMed
  7. Heart. 2003 Nov;89(11):1363-72 - PubMed
  8. J Clin Epidemiol. 1994 Nov;47(11):1245-51 - PubMed
  9. J Manag Care Pharm. 2005 Apr;11(3):240-51 - PubMed
  10. Eur J Anaesthesiol. 1996 Jul;13(4):364-8 - PubMed
  11. Br J Clin Pharmacol. 2010 Dec;70(6):881-5 - PubMed
  12. Circulation. 2010 Mar 2;121(8):1047-60 - PubMed
  13. Int Heart J. 2010;51(5):365-6 - PubMed
  14. J Chronic Dis. 1987;40(5):373-83 - PubMed
  15. Arch Intern Med. 2005 May 23;165(10):1111-6 - PubMed
  16. Exp Physiol. 1996 Jul;81(4):587-603 - PubMed
  17. Circulation. 2004 Oct 26;110(17):2721-46 - PubMed
  18. Prog Cardiovasc Dis. 2003 Mar-Apr;45(5):415-27 - PubMed
  19. Anaesthesia. 2010 Jul;65(7):679-83 - PubMed
  20. Am J Physiol Heart Circ Physiol. 2008 Dec;295(6):H2264-72 - PubMed
  21. Br J Pharmacol. 2010 Jan;159(1):49-57 - PubMed
  22. Ann Pharmacother. 2012 Jul-Aug;46(7-8):960-71 - PubMed
  23. Clin Pharmacokinet. 2011 Nov 1;50(11):739-50 - PubMed
  24. Emerg Med Australas. 2008 Oct;20(5):437-40 - PubMed
  25. Anesthesiology. 1994 Mar;80(3):534-44 - PubMed
  26. Ann Noninvasive Electrocardiol. 2003 Oct;8(4):343-51 - PubMed
  27. Kaohsiung J Med Sci. 2010 Sep;26(9):470-7 - PubMed
  28. Anesthesiology. 2002 Jul;97(1):265-6 - PubMed
  29. J Clin Pharmacol. 2011 May;51(5):719-30 - PubMed
  30. Chest. 2012 May;141(5):1327-36 - PubMed
  31. Anesth Analg. 2003 Sep;97(3):657-62 - PubMed
  32. Anesth Analg. 2000 Jan;90(1):25-7 - PubMed
  33. Acta Anaesthesiol Scand. 2014 Mar;58(3):266-72 - PubMed
  34. Anaesthesia. 2008 Oct;63(10):1061-4 - PubMed
  35. Chest. 2007 Dec;132(6):2020-9 - PubMed
  36. JAMA. 1997 Jan 22-29;277(4):301-6 - PubMed
  37. Anesthesiology. 2003 Sep;99(3):764 - PubMed
  38. Br J Pharmacol. 1992 Oct;107(2):559-65 - PubMed
  39. Br J Clin Pharmacol. 2013 Jul;76(1):48-57 - PubMed
  40. Acta Anaesthesiol Scand. 1990 May;34(4):276-81 - PubMed

Publication Types